CO5580837A2 - Vacuna dna que codifica al menos dos proteinas tempranas no estructurales de papilomavirus - Google Patents
Vacuna dna que codifica al menos dos proteinas tempranas no estructurales de papilomavirusInfo
- Publication number
- CO5580837A2 CO5580837A2 CO05040562A CO05040562A CO5580837A2 CO 5580837 A2 CO5580837 A2 CO 5580837A2 CO 05040562 A CO05040562 A CO 05040562A CO 05040562 A CO05040562 A CO 05040562A CO 5580837 A2 CO5580837 A2 CO 5580837A2
- Authority
- CO
- Colombia
- Prior art keywords
- papilomavirus
- dna vaccine
- early proteins
- polynucleotide
- vaccine coding
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 241000701806 Human papillomavirus Species 0.000 abstract 3
- 108020004705 Codon Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Una secuencia de polinucleótidos que codifica un polipéptido de papilomavirus humano (HPV) que tiene epítopos de al menos tres antígenos tempranos o fragmentos de los mismos de al menos dos cepas diferentes de HPV, y en donde el polinucleótido tiene un coeficiente de uso de codones para genes humanos mayor que 0.4 y menor que 1.0.14.- Un vector de expresión que comprende una secuencia de polinucleótidos según cualquiera de las reivindicaciones precedentes unida operativamente a una secuencia de control que es capaz de proporcionar la expresión de la secuencia de polinucleótidos mediante una célula hospedadora.16.- Una composición farmacéutica que comprende una secuencia de polinucleótidos según una cualquiera de las reivindicaciones 1 - 13.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0222953.2A GB0222953D0 (en) | 2002-10-03 | 2002-10-03 | Novel Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5580837A2 true CO5580837A2 (es) | 2005-11-30 |
Family
ID=9945247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05040562A CO5580837A2 (es) | 2002-10-03 | 2005-04-28 | Vacuna dna que codifica al menos dos proteinas tempranas no estructurales de papilomavirus |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20060165713A1 (es) |
| EP (1) | EP1546191A2 (es) |
| JP (1) | JP2006516386A (es) |
| KR (1) | KR20050050115A (es) |
| CN (1) | CN100393878C (es) |
| AR (1) | AR041515A1 (es) |
| AU (1) | AU2003294672A1 (es) |
| BR (1) | BR0314986A (es) |
| CA (1) | CA2500093A1 (es) |
| CO (1) | CO5580837A2 (es) |
| GB (1) | GB0222953D0 (es) |
| IS (1) | IS7775A (es) |
| MA (1) | MA27474A1 (es) |
| MX (1) | MXPA05003558A (es) |
| NO (1) | NO20051561L (es) |
| NZ (1) | NZ539154A (es) |
| PL (1) | PL376534A1 (es) |
| RU (1) | RU2354701C2 (es) |
| TW (1) | TW200411055A (es) |
| WO (1) | WO2004031222A2 (es) |
| ZA (1) | ZA200503201B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1556077A2 (en) | 2002-10-29 | 2005-07-27 | Coley Pharmaceutical Group, Ltd | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
| CN101617052A (zh) * | 2007-01-30 | 2009-12-30 | 特兰斯吉恩股份有限公司 | 用于免疫的乳头瘤病毒e2多肽 |
| GB0710538D0 (en) * | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Vaccine |
| EP2585107B1 (en) | 2010-06-25 | 2018-10-24 | Vaccibody AS | Homodimeric protein constructs |
| MY195018A (en) * | 2014-10-24 | 2023-01-03 | Hpvvax Llc | Cancer and skin lesion treatment |
| US20190134190A1 (en) * | 2016-05-04 | 2019-05-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN443995A0 (en) * | 1995-07-27 | 1995-08-17 | Csl Limited | Papillomavirus polyprotein |
| WO2002008435A1 (en) * | 2000-07-21 | 2002-01-31 | Glaxo Group Limited | Codon-optimized papilloma virus sequences |
| GB0017990D0 (en) * | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Papilloma virus sequences |
-
2002
- 2002-10-03 GB GBGB0222953.2A patent/GB0222953D0/en not_active Ceased
-
2003
- 2003-10-01 AU AU2003294672A patent/AU2003294672A1/en not_active Abandoned
- 2003-10-01 CA CA002500093A patent/CA2500093A1/en not_active Abandoned
- 2003-10-01 NZ NZ539154A patent/NZ539154A/en unknown
- 2003-10-01 WO PCT/EP2003/011158 patent/WO2004031222A2/en active Application Filing
- 2003-10-01 BR BR0314986-2A patent/BR0314986A/pt not_active IP Right Cessation
- 2003-10-01 US US10/529,931 patent/US20060165713A1/en not_active Abandoned
- 2003-10-01 PL PL376534A patent/PL376534A1/pl not_active Application Discontinuation
- 2003-10-01 EP EP03785608A patent/EP1546191A2/en not_active Withdrawn
- 2003-10-01 MX MXPA05003558A patent/MXPA05003558A/es not_active Application Discontinuation
- 2003-10-01 JP JP2004540797A patent/JP2006516386A/ja active Pending
- 2003-10-01 TW TW092127210A patent/TW200411055A/zh unknown
- 2003-10-01 KR KR1020057005806A patent/KR20050050115A/ko active IP Right Grant
- 2003-10-01 CN CNB2003801049852A patent/CN100393878C/zh not_active Expired - Fee Related
- 2003-10-01 RU RU2005109155/13A patent/RU2354701C2/ru not_active IP Right Cessation
- 2003-10-03 AR ARP030103608A patent/AR041515A1/es unknown
-
2005
- 2005-03-23 NO NO20051561A patent/NO20051561L/no not_active Application Discontinuation
- 2005-03-29 IS IS7775A patent/IS7775A/is unknown
- 2005-04-15 MA MA28223A patent/MA27474A1/fr unknown
- 2005-04-20 ZA ZA200503201A patent/ZA200503201B/en unknown
- 2005-04-28 CO CO05040562A patent/CO5580837A2/es not_active Application Discontinuation
-
2007
- 2007-06-08 US US11/760,127 patent/US20070264283A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2354701C2 (ru) | 2009-05-10 |
| AU2003294672A1 (en) | 2004-04-23 |
| GB0222953D0 (en) | 2002-11-13 |
| JP2006516386A (ja) | 2006-07-06 |
| AR041515A1 (es) | 2005-05-18 |
| PL376534A1 (pl) | 2006-01-09 |
| MXPA05003558A (es) | 2005-06-03 |
| CA2500093A1 (en) | 2004-04-15 |
| RU2005109155A (ru) | 2006-03-10 |
| KR20050050115A (ko) | 2005-05-27 |
| CN100393878C (zh) | 2008-06-11 |
| NO20051561L (no) | 2005-06-02 |
| BR0314986A (pt) | 2005-08-09 |
| US20070264283A1 (en) | 2007-11-15 |
| CN1720261A (zh) | 2006-01-11 |
| WO2004031222A3 (en) | 2004-08-19 |
| TW200411055A (en) | 2004-07-01 |
| EP1546191A2 (en) | 2005-06-29 |
| MA27474A1 (fr) | 2005-08-01 |
| ZA200503201B (en) | 2006-06-28 |
| NO20051561D0 (no) | 2005-03-23 |
| WO2004031222A2 (en) | 2004-04-15 |
| NZ539154A (en) | 2007-05-31 |
| IS7775A (is) | 2005-03-29 |
| US20060165713A1 (en) | 2006-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5580837A2 (es) | Vacuna dna que codifica al menos dos proteinas tempranas no estructurales de papilomavirus | |
| GEP20084431B (en) | Papilloma virus vaccine | |
| DK1108035T3 (da) | Behandling af cervixcancer | |
| ES2263406T1 (es) | Produccion de proteina capsida l1 y particulas tipo virus de papilomavirus humano hbv-11. | |
| AR057213A1 (es) | Acidos nucleicos que codifican secuencias tgev y prrsv para la expresion mejorada de secuencias prrsv | |
| DK0462187T3 (da) | Farmaceutisk præparat, som kan anvendes til forebyggelse eller behandling af papillomvirusinducerede tumorer | |
| DE60130987D1 (de) | Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps) | |
| CY1110525T1 (el) | Βελτιστοποιημενη εκφραση της hpv 45 li σε ζυμη | |
| WO2008011609A3 (en) | Compositions and methods for vaccinating against hsv-2 | |
| DE69535018D1 (de) | Papillomavirus vakzine | |
| BRPI0417509A (pt) | molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira | |
| BR112017009177A2 (pt) | vacinas terapêuticas contra hpv16 | |
| ECSP045300A (es) | Antígenos virales | |
| BRPI0416393A (pt) | molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, métodos para produzir as mesmas, para prevenir infecção por hpv, e para induzir uma resposta imune em um animal, vacina, composições farmacêuticas, e, polipeptìdeo hpv58 l1 isolado e purificado | |
| PT1212358E (pt) | Genes sinteticos de papilomavirus humano | |
| CY1109257T1 (el) | Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων | |
| AR051923A1 (es) | Secuencias de acidos nucleicos que codifican proteinas capaces de asociarse en particulas tipo virus | |
| BR0016145A (pt) | Clones infecciosos | |
| NO20062948L (no) | Promotere for ekspresjon i modifisert vaccinia-virus Ankara | |
| ATE354662T1 (de) | Modifizierte hpv e6- und e7-gene und -proteine als impfstoff | |
| DK1425404T3 (da) | Vaccinia-MVA-E3L-mutanter og anvendelse deraf | |
| WO2001087350A3 (en) | Treatment of human papillomavirus (hpv)-infected cells | |
| ATE101200T1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
| DK1290160T3 (da) | Humane Pellino-polypeptider | |
| DE3585578D1 (de) | Hepatitisoberflaechenantigenpartikelvakzin. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |